|By David Sell, The Philadelphia Inquirer|
|McClatchy-Tribune Information Services|
"Be aware," Gorsky said, that cost-containment efforts must "ensure we continue to reward innovation," or risk not having new drugs to treat health problems.
"By focusing only on costs, we will not cure Alzheimer's, we will not take care of diabetes in a way we should," Gorsky told
Everybody -- patients, employers, hospitals, insurers, drug companies -- says they like the idea of spending less on health care, but everybody prefers the savings come from somebody else. Amid fiscal debates, most segments of health care are being pressured to reduce prices.
Price pressure was part of every discussion about J&J's three main divisions: prescription pharmaceuticals, medical devices and consumer products. Of the three, medical devices generate the most revenue for J&J since it completed the
J&J's headquarters is in
Though it was born and officially headquartered in
J&J reported yearly sales increased from
On the strength of new revenue from the Synthes acquisition in 2012, and a
Gorsky also said J&J was "absolutely committed" to keeping its
McNeil makes over-the-counter consumer brands such as Tylenol and Motrin, but the
Gorsky said J&J has met its milestones to date for eventual recertification of the plant by the
Meanwhile, Gorsky said J&J is "initiating the first steps" in exploring the sale of its
(c)2013 The Philadelphia Inquirer
Visit The Philadelphia Inquirer at www.philly.com
Distributed by MCT Information Services
We have detected you are using an adblocker. If you wish to enjoy our content please disable your adblocker and click the button below.